. Emerging evidence suggests that both genetic alterations and epigenetic aberrations contribute to the initiation and progression of human cancers 3 . For example, aberrant DNA methylation is a common mechanism used by tumour cells to silence tumour suppressor genes 4 . In this Review, we focus on the recent advances that link oncogenesis to histone methylation events, with those occurring at histone H3 lysine 4 (H3K4) and H3 lysine 27 (H3K27) as paradigmatic examples (TABLE 1) . We propose that epigenetic alterations involving histone modifications lead to the misregulation of gene expression and consequently tumorigenesis.
Methylation of histones can occur at both lysine and arginine resides and is now appreciated as a reversible process. Its homeostasis is mediated by two antagonizing groups of enzymes, histone methylation 'writers' and 'erasers' , which install and remove histone methylation marks, respectively, in a site-specific manner 1, 5 . For example, H3K4 methylation is established by the SET1 and mixed lineage leukaemia (MLL) family of histone methyltransferases (HMTs) 5 (FIG. 1a) , and removed by the lysine-specific histone demethylase 1 (LSD1) and jumonji AT-rich interactive domain 1 (JARID1) family of histone demethylases (HDMs) 6 (TABLE 1) .
For histone H3, methylation has been observed at multiple lysine sites, including H3K4, K9, K27, K36 and K79, and the addition of up to three methyl groups at each lysine produces a total of four methyl states: unmethylated, monomethylated, dimethylated or trimethylated. These histone methylation states exhibit a distinct distribution pattern in the mammalian genome 7 . H3K4 trimethylation (H3K4me3) is strongly associated with transcriptional competence and activation, with the highest levels observed near transcriptional start sites of highly expressed genes, whereas H3K27 trimethylation (H3K27me3) is frequently associated with gene silencing, especially the repression of unwanted differentiation programmes during lineage specification [7] [8] [9] . The distribution patterns of H3K4me3, H3K27me3 and their associated histone marks underlie the diversity of cellular states for pluripotency and lineage differentiation. For example, in embryonic stem cells, active and repressive (bivalent) histone modifications coexist on developmentally crucial genes. By contrast, monovalent active or repressive histone marks are often found on these genes in differentiated cell lineages 8, 9 . The bivalent chromatin state has been suggested as a mechanism for retaining chromatin and cellular plasticity at early stages of development 8, 9 . As epigenetics and histone modification have crucial roles in cell fate determination, it has been proposed that they
Epigenetic
Refers to the study of mechanisms underlying inheritable phenotypic variations caused by DNA sequence-independent alterations. This term has been more loosely used to describe alterations caused by a change of chromatin structure, which often have unclear heritability.
DNA methylation
A type of chemical modification of DNA that involves the addition of a methyl group to the number 5 carbon of the cytosine pyrimidine ring.
Histone methylation
A chemical modification involving the addition of one, two or three methyl groups on the lysine or arginine residues in a histone protein.
General transcription machinery
A large protein complex including RNA polymerase II and general transcription factors such as TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH.
may help establish tumour-initiating cell populations in early tumorigenesis 10 . Indeed, changes in global histone modification patterns have been observed in several types of cancer, and these studies have provided us with the first glimpse of how the epigenetic landscape and cellular context might be altered in tumorigenesis 11, 12 .
Histone methylation: a chromatin index one important issue in chromatin biology and epigenetics is how the pattern of a potential histone code or epigenetic code (BOX 1) is translated into meaningful biological consequences, and the identification of factors that specifically recognize or read histone modifications has greatly contributed to our mechanistic understanding. A recent breakthrough was the discovery of a specialized group of protein modules, plant homeodomain (PHD) fingers (BOX 2) , which function as the specific reading motif for trimethylated and dimethylated H3K4 (H3K4me3/2), with H3K4me3 as the preferred ligand [13] [14] [15] [16] (TABLE 2) . Although many PHD finger motifs are encoded by the human genome, only a subset contains the crucial hydrophobic and aromatic residues that can form a specialized structural pocket to accommodate the H3K4me3 side chain 5
. These PHD histone modification reading modules have been reviewed in detail elsewhere 5, 17, 18 . Here, we focus only on how these histone modification reading factors are involved in normal cellular processes, such as transcriptional regulation, as well as in oncogenesis.
Around 15 PHD finger-containing readers for H3K4me3/2 have been experimentally confirmed (TABLE 2) , and these include an RNA polymerase IIassociated general transcription machinery component TFIID subunit 3 (also known as TAF3), a V(D)J recombinase RAG2, and several key chromatin-modifying and remodelling factors. The H3K4me3 mark could be a crucial chromatin 'index' mechanism, allowing specific genomic regions to be readily recognized by their downstream readers and/or associated effectors. For example, the targeting of TFIID to H3K4me3 at promoters has been suggested to help anchor and/or recruit TFIID and associated machinery for active transcriptional initiation 19, 20 (FIG. 2a) . The recognition of H3K4me3 by the RAG2 PHD finger at v(D)J gene segments is crucial for efficient v(D)J recombination during B and T cell development and maturation, and deleterious germline mutations that abrogate such recognition of H3K4me3 lead to severe immunodeficiency syndromes 21 (FIG. 2b) . Now, emerging evidence also reveals that deregulation in the reading of H3K4me3 contributes to cellular transformation and tumorigenesis, for example, in acute myeloid leukaemia that is induced by chromosomal translocation of the H3K4me3-reading PHD finger of PHF23 or JARID1A (also known as KDM5A and RBBP2) 22 (TABLE 1) . Furthermore, many enzymes that mediate the writing and erasing of histone methylation are strongly associated with oncogenesis (TABLE 1) . Notably, some histone methylation writers and erasers also contain the methyl-reading module (for example, MLL and JARID1A (TABLEs 1,2)), indicating potential coordination between the reading, writing and erasing events of histone modification.
demethylation of histones and beyond Although histone modification writers and erasers were originally identified as enzymes that modify histones, recent evidence suggests that they may also target nonhistone proteins, which might confound attempts to infer the function of histone modifications. For example, LSD1 not only targets its canonical substrate, histone H3, but also demethylates the tumour suppressor p53 at lysine 370 and represses p53 activities 23, 24 . Similarly, the histone methyltransferases G9a, SET7 and SET9 induce the methylation of many non-histone proteins 24, 25 . To our knowledge, none of the histone methyltransferases and demethylases listed in TABLE 1 has been shown to function on non-histone substrates; however, this remains a formal possibility. Bearing in mind these potential caveats, in the following sections, we use mutations affecting H3K4me3-reading PHD finger readers, and mutations affecting chemical modification of H3K4me3 and H3K27me3, as instructive examples to discuss recent evidence that links the miswriting, misinterpretation and mis-erasing of the histone code to oncogenesis.
Histone methylation miswritten in cancer
The establishment of an appropriate pattern of histone methylation is not only crucial for normal development and differentiation, but is also intimately associated with tumour initiation and development (TABLE 1) .
at a glance
• Post-translational modifications of histones introduce meaningful variations into chromatin and provide a regulatory platform for controlling and/or fine-tuning many important DNA-templated processes, including gene transcription, the repair of DNA damage and DNA replication.
• Histone modifications, together with factors responsible for adding ('writing'), interpreting ('reading') and removing ('erasing') histone modifications, regulate specific and distinct functional outputs of our genomes, which constitute the basis of the 'histone code hypothesis'.
• As recent evidence starts to link the miswriting, misinterpretation and mis-erasing of histone modifications to oncogenesis, we further propose that misregulation of the histone code leads to deregulated gene expression and perturbation of cellular identity, and is therefore a major contributor to cancer initiation, progression and/or metastasis.
• Mixed lineage leukaemia (MLL) and enhancer of zeste 2 (EZH2) catalyse the addition of methylation of histone H3 lysine 4 (H3K4) and H3 lysine 27 (H3K27), respectively, which are arguably two of the most important histone methylation marks. MLL rearrangement and deregulation of EZH2 are among the most common mutations in leukaemia and solid tumours, respectively.
• Several plant homoedomain (PHD) finger-containing proteins have recently been identified as reading factors of trimethylation of H3K4 (H3K4me3). Misinterpretation of H3K4me3 by leukaemia-associated translocations of PHD finger factors (NUP98-JARID1A or NUP98-PHF23) is crucial for the induction of myeloid leukaemia; somatic mutations of ING1, a PHD finger factor, interfere with the reading of H3K4me3 and associate with the development of oesophageal squamous cell carcinoma, head and neck squamous cell carcinoma and melanoma.
• Deregulation or mutations of the recently identified H3K4-or H3K27-specific histone demethylases have been observed in solid tumours. However, their involvement in cancer development and underlying mechanisms are largely unclear. , and was later shown to encode a major H3K4-specific HMT enzyme 28, 29 . MLL forms a large macromolecular nuclear complex with the core complex components (WDR5, RBBP5 and ASL2) and induces H3K4me3 for efficient transcription 5, 28, 30 (FIG. 1a) . other MLL-associated factors, menin (also known as MEN1) and LEDGF, tether the MLL complex to appropriate targets 31 (FIG. 1a) . MLL gene rearrangement is one of the most common chromosomal abnormalities in human leukaemia, accounting for around 80% of infant leukaemia and 5-10% of adult acute myeloid leukaemia (AML) or lymphoid leukaemia 27, 32 .
V(D)J recombinase
The partial tandem duplication of MLL (MLL-PTD), the most frequent form of MLL rearrangement in AML 32, 33 , contains an in-frame duplication of MLL exon 4 to 11 (or exon 4 to 12) and retains the H3K4 HMT activity 27 (FIG. 1a) . Dorrance et al. 34 have recently generated an MLL-PTD knock-in mouse model and found that MLL-PTD causes aberrant elevation of H3K4 dimethylation and histone acetylation of the HoXA gene cluster 34, 35 (FIG. 1a) . overexpression of Hox genes promotes leukaemia induction 36 . Normally, the expression of HoXA genes such as Hoxa9 is developmentally restricted: they are highly expressed in early haematopoietic precursors and silenced following differentiation 37 (FIG. 1a) . In the MLL-PTD knock-in mice, increased histone methylation and acetylation correlates with a significant increase in the colony formation potentials of erythroid, myeloid and pluripotent haematopoietic progenitors in vitro, as well as a drastic increase in Hoxa9 expression among terminally differentiated blood cells (increased by ~100-250-fold) and unsorted haematopoietic tissues (by ~4-150-fold) 34, 35 . However, these MLL-PTD knock-in mice fail to develop frank leukaemia, indicating that additional alterations are required for malignant transformation.
MLL fusions, a second type of MLL gene rearrangement, result in the deletion of a large carboxy terminal fragment, which includes the H3K4 HMT domain, and also the acquisition of additional transformation mechanisms provided by MLL fusion partners 27, 38 (FIG. 1b,c,d ). More than 50 different MLL fusion partners have been identified in leukaemia 27, 38 . Although the leukaemogenic mechanisms underlying many rare MLL fusion forms remain poorly understood, recent studies have unveiled a common transformation pathway for the most frequent MLL fusion forms (FIG. 1b,c) . okada et al. first reported that the AF10 portion of MLL-AF10 (REF. 39 ) and CALM-AF10 (REF. 40 ) fusions directly recruits DoT1L (also known as KMT4), a histone methyltransferase that writes the methy lation of histone H3 lysine 79 (H3K79me) 39 (FIG. 1b) , a key event in MLL-AF10-driven leukaemogenesis. Similarly, the ENL component of the MLL-ENL fusion also directly associates with DoT1L, and subsequently drives leukaemogenesis 41 (FIG. 1b) . Aberrant induction of H3K79me was observed at leukaemia-promoting oncogenes (such as Hoxa9 (FIG. 1b) 39, 43 , thus providing a potential mechanism for the aberrant transcriptional activation found in leukaemia. DoT1L and by inference, H3K79me, are also involved in cell cycle progression 47 , silencing of telomere-proximal genes 48 and regulation of Wnt-target genes 49 . 41, 49, 50 , AF5q31 (also known as
Box 1 | the histone code hypothesis
The histone code hypothesis, initially proposed by Allis and colleagues 1, 2 , refers to an epigenetic marking system using different combinations of histone modification patterns to regulate specific and distinct functional outputs of eukaryotic genomes.
The histone code hypothesis in gene regulation and development
The histone code hypothesis proposes several layers of regulation in the interpretation of the genome. First, the establishment of homeostasis of a combinatorial pattern of histone modification -the histone code -in a given cellular and developmental context is brought about by a series of 'writing' and 'erasing' events carried out by histone-modifying enzymes. Here, the writer of histone modification refers to an enzyme (for example, a histone methyltranferase) that catalyses a chemical modification of histones in a residue-specific manner, and the eraser of histone modification refers to an enzyme (for example, a histone demethylase) that removes a chemical modification from histones 1, 2, 5 . Second, the specific interpretation or the 'reading' of the histone code; this is accomplished by reader or 'effector' proteins that specifically bind to a certain type or a combination of histone modification and translate the histone code into a meaningful biological outcome, whether transcriptional activation, silencing or other cellular responses 1, 2, 5 . In addition to such a recruitment or trans mechanism, the manifestation of histone modification can be also achieved by direct physical modulation of chromatin structure or alteration of intra-nucleosomal and inter-nucleosomal contacts through steric or charge interaction (for example, neutralization of the positive charges of histones by acetylation of lysines) [1] [2] [3] . All these regulatory mechanisms function broadly to set up an epigenetic landscape that determines cell fate decision-making during embryogenesis and development 9 , and fine-tunes gene transcriptional output at a few gene loci during DNA damage repair 14 or other DNA-templated contexts.
The histone code hypothesis extended to oncogenesis
In the contexts of tumorigenesis and cancer epigenetics, we further propose that alteration in the homeostasis between epigenetically regulated gene-on versus gene-off chromatin states leads to inappropriate expression or silencing of transcriptional programmes that consequently alter the states of cellular identity. In certain developmental cell lineages, these alterations lead to undesirable outcomes: proliferation versus senescence and/or differentiation during tumorigenesis.
Transcription elongation
Efficient transcription and productive RNA processing after RNA polymerase II (Pol II) and associated factors have escaped from abortive initiation, a phenomenon in which Pol II and transcription are halted at promoter-proximal pause sites.
MCEF and AFF4) 41 and LAF4 (REF. 41 ). AF10, AF17 and ENL (or AF9) were identified as stable components of DoT1L-containing complexes 49 . one intriguing model is that DoT1L is responsible for aberrant transcription in many MLL fusion-induced leukaemias; however, this is complicated by the fact that DoT1L complexes are also linked to transcription elongation. Through a protein-protein interaction network, DoT1L-AF10-ENL complexes further associate with a transcription elongationpromoting complex that contains AF5q31, AF4, ELL1, ELL2 and ELL3 (also known MLL fusion partners), and the Pol II transcription elongation factor b (P-TEFb) kinase (which consists of CDK9, cyclin T1 and cyclin T2) 41, 53 (FIG. 1b,c ). ENL and AF5q31 are shared components of these two complexes 41, 49, 51, 53 . In addition, two recent studies further demonstrate that MLL fusions involving components in this elongation complex -such as MLL-AF4, MLL-ENL, MLL-AF9 and MLL-ELL1 -all interact with AF5q31 and recruit P-TEFb transcription elongation complexes to promote the transcription of downstream targets such as Hox 53, 54 (FIG. 1c) . Therefore, mechanisms underlying aberrant transactivation in MLL leukaemia have been linked to H3K79me and also transcription elongation.
Although the activities of the P-TEFb complexes during transcription are well established, the role of H3K79 methylation in transcription is less well understood. Is H3K79me as important as P-TEFb, or does DoT1L merely bridge MLL fusions (such as MLL-ENL and MLL-AF10) to P-TEFb elongation complexes (FIG. 1b) ? Several lines of evidence suggest that H3K79me is crucial in leukaemia induction. First, replacing the AF10 fragment of MLL-AF10 with the wild-type, but not the catalytically inactive, form of DoT1L led to • AF4
• AF5q31
• ELLs leukaemic transformation 39 . Second, RNA interference (RNAi)-mediated inhibition of DoT1L significantly impaired MLL-AF4-induced transformation and the activation of Hox genes 43 , despite intact association of MLL-AF4 with AF5q31 and the P-TEFb elongation complexes 53 . In addition, DoT1L directly interacts with P-TEFb 54 . Further investigations will be needed to examine the role of H3K79me during transcriptional activation and elongation in leukaemogenesis.
Another MLL fusion, MLL-EEN, recruits histone arginine methyltransferase PRMT1, and its methyltransferase activity towards histone H4 arginine 3 has been shown to be important for leukaemia transformation 55 (this also occurs through Hoxa9 activation (FIG. 1d) ). Taken together, miswriting of histone methylation marks often correlates with the aberrant transcription of oncogenes in patients with leukaemia harbouring MLL gene rearrangements.
EZH2 overexpression and mutation in cancers.
Enhancer of zeste homolog 2 (EZH2), an H3K27-specific methyltransferase, provides another connection between miswriting histone methylation marks and oncogenesis. EZH2 is frequently found overexpressed in various solid tumours, including prostate, breast, colon, skin and lung cancer 56, 57 (TABLE 1) . Suppression of EZH2 by RNAi significantly decreased tumour growth in breast and prostate tumour xenograft models 58, 59 . Furthermore, overexpression of EZH2 confers invasiveness to fibro blasts and immortalized benign mammary epithelial cells, and this effect is dependent on the H3K27 HMT activity of EZH2 (REFs 59-61). Mechanistically, the oncogenic function of EZH2 has been attributed to the silencing of tumour suppressor genes, including InK4b-Arf-InK4A 57 (FIG. 1e) (TABLE 1) . The identified EZH2 mutations specifically target a single tyrosine residue that is required for EZH2-mediated HMT activities towards H3K27me3 (REF. 65 ). It is tempting to speculate that the homeostasis of H3K27me3 is crucial in defining cellular context, and its perturbation through EZH2 deregulation might provide the optimal context for the development of distinct types of cancer; for example, differences in H3K27me3 homeostasis may underlie some differences in prostate cancer and follicular lymphoma. The precise roles of EZH2 overexpression and loss-of-function mutations in distinct cancer types remain to be more rigorously validated in genetically engineered animal models. Ideally, genomic mislocalization of EZH2 and its effect on H3K27me3 and transcription need to be examined in genetically matched normal samples compared with tumour samples. Nevertheless, EZH2 inhibition has been proposed as a therapeutic strategy to inhibit tumour growth 56 . Indeed, early success for the combined use of the EZH2 inhibitor and histone deacetylase (HDAC) inhibitors has been observed in leukaemia xenograft mouse models 66 . Recent comprehensive reviews 56, 57 provide further details on EZH2 in oncogenesis.
Histone methylation misread in cancer Aberrant fusion of PHD finger motifs and misinterpretation of H3K4me3 in leukaemia. Chromosomal translocation of nucleoporin 98 (nUP98), a nuclear pore complex component gene, is one of the most promiscuous gene rearrangements found in various forms of haematopoietic malignancies 67 . In a subset of patients with AML, NuP98 translocation results in the fusion of the amino terminus of NuP98 to the C-terminal PHD finger motif (and also nuclear localization signals) of PHF23 or JARID1A 22, 67 (FIG. 2c) . Recently, leukaemia induced by NuP98-JARID1A and NuP98-PHF23 fusions has been experimentally recapitulated using in vitro and in vivo mouse models 22 . The leukaemogenic potential of these two fusion proteins relies on the ability of the PHD finger motif to recognize H3K4me3/2 (REF. (REFs 22, 68) . As a result, the master regulator loci of haematopoiesis are locked in an active chromatin state that is characterized by high levels of H3K4me3 and histone acetylation; consequently, the expression of these genes is maintained 22 . overexpression and activating mutations of these transcription factors are commonly found in human leukaemia and are sufficient
Box 2 | the plant homeodomain (pHd) finger
The PHD finger is a zinc finger-like domain, with a signature motif of Cys4-His-Cys3 to coordinate two zinc ions 120 . The folding of this ~60 amino acid-long domain is featured by an interleaved topology of zinc ion-coordinating residues and a couple of anti-parallel β-sheet secondary structures 5, 120 . The definition of PHD fingers originates from conserved plant homeodomain proteins, and the classification and distinction of PHD fingers and other similar motifs such as the RING finger are somewhat ambiguous 120 . There are fewer than 20 typical and atypical PHD finger motifs in Saccharomyces cerevisiae, around 50 in Drosophila melanogaster and up to a couple of hundred in mammals 18, 120, 121 . Most PHD fingers are found in chromatin-associated factors or nuclear proteins 120, 121 .
The PHD finger ligand PHD fingers exhibit diversity and versatility in their interaction partners. Some bind to chromatin modifications, such as highly methylated H3K4 (REF. . The binding partners and functions of others are still unknown.
The structure of H3K4me3/2-binding PHD fingers Recent structural analyses of several H3K4me3/2-binding PHD fingers have revealed some commonalities that underlie the specific recognition and binding of H3K4me3, which include a specialized pocket or cleft structure formed by 2-4 aromatic and/or hydrophobic residues to accommodate the H3K4me3 side chain, anti-parallel β-sheet pairing between the histone H3 backbone and a β-sheet of the PHD motif and, in many cases, positioning of H3 arginine 2 (H3R2) in an acidic pocket 5, [15] [16] [17] [20] [21] [22] . The structures of H3K4me3-binding PHD fingers from two cancer-associated factors, ING2 and JARID1A, are shown in the figure part a and part b, respectively (H3 and the H3K4me3 side chain shown in green, PHD finger in lilac, zinc ion in cyan sphere and hydrophobic 'pocket' highlighted in pink; arrows represent β-sheets). With a dissociation constant (K d ) ranging from less than one to several μM, the binding of H3K4me3 by PHD fingers is one of the strongest associations between histone modification and its reading factors 5, [15] [16] [17] [20] [21] [22] . The structural illustrations shown are produced using published structural coordinates that have Protein Data Bank IDs of 2G6Q, 3GL6, 2KGG and 2KGI 16, 22 .
Chromatin dynamics
A fine-tuning mechanism that introduces meaningful variations to chromatin and/or modulate chromatin structure, which includes DNA methylation, covalent histone modification, ATP-dependent chromatin remodelling and the use of histone variants.
Chromatin boundary factor
A factor that interacts with chromatin boundary elements to ensure the appropriate physical separation of chromatin regions that have distinct properties such as regions of active versus silenced transcription. One example is CTCF, a protein that binds to insulator cis-elements.
to block haematopoietic differentiation and induce leukaemia 36, 69 . Therefore, the perturbation of histone modification dynamics associated with haematopoiesis, as in the case of NuP98-PHD finger fusion, causes the enforced expression of vital developmental genes and interferes with appropriate transition of cellular statesa crucial step in leukaemia initiation 22 . In many cases, acute leukaemia is a disease of misregulated differentiation in haematopoiesis. The key to understanding how NuP98 or MLL translocations interfere with chromatin dynamics in leukaemogenesis is to first understand the mechanisms underlying the chromatin landscape changes during normal haematopoiesis. Conceivably, NuP98-PHD finger fusions might mimic some endogenous chromatin-associated machinery, functioning as a chromatin boundary factor that prevents the intrusion of transcriptional repressive complexes 22 . In this case, NuP98-PHD finger fusions could have a dominant-negative effect on JARID1, blocking the erasure of H3K4me3 (REF. 22 ); acetylation of H3K27 that is induced by NuP98-associated HATs can also antagonize the methylation of the same lysine by EZH2 complexes 22, 70 (FIGs 2c,3b) . Gain-of-function mutations in the PHD finger motif -for example, NuP98-PHD finger fusions in leukaemia 22 -and loss-of-function mutations in the PHD finger, as mentioned earlier for RAG2 and immunodeficiency syndromes 21 , unveil pathologies underscored by a failure to appropriately interpret histone modification 18 .
Somatic mutation of ING PHD fingers in solid tumours.
Another family of PHD finger-containing proteins, inhibitor of growth (ING), are putative tumour suppressors. Loss-of-function mutations of INGs (especially InG1, InG3 and InG4) by somatic mutation, allelic loss, reduced gene expression and aberrant cytoplasmic sequestration have been reported in various solid tumours 71, 72 (TABLE 1) . INGs regulate many cellular processes that are associated with tumorigenesis, including cell cycle progression, senescence, apoptosis, DNA repair, cell migration and contact inhibition [71] [72] [73] [74] . All INGs have a C-terminal PHD finger that specifically binds H3K4me3 (REFs 14,75-77) (BOX 2). Despite this common feature, different INGs are incorporated into protein complexes with distinct properties in transcriptional regulation (TABLE 2) . ING1 and ING2 recruit the mSin3-HDAC transcriptional repressors (FIG. 2d) and modulate its activity 71, [79] [80] [81] . Here, we focus on recent advances that link ING mutations to the misinterpretation of histone methylation in transformation.
InG1 was initially identified in a functional screen as an inhibitor of neoplastic transformation 82 , and somatic mutation of InG1 was later found in breast, gastric and pancreatic cancer, and squamous cell carcinoma 71, 72 . Deletion of Ing1 in mice led to a mild phenotype only, with a slight increase in the incidence of lymphomas, indicating that other mutations may cooperate with InG1 inactivation in tumorigenesis 79 . A subset of InG1 somatic mutations found in human tumour samples specifically target its PHD finger motif 18, [71] [72] [73] . Some hotspot mutations, such as C215S and C253stop (the amino acid number refers to the p33
ING1b isoform), target the crucial zinc ioncoordinating cysteines in the PHD finger, causing global misfolding 18 . A recent biophysical study demonstrated that other InG1 mutations, N216S, v218I and G221v, interfere with either appropriate folding of the structural pocket to accommodate H3K4me3 or the appropriate positioning of the histone H3 tail, leading to a decrease in H3K4me3-binding affinities by 10-40-fold 75 . Despite these advances, animal models that establish a direct causal role of InG1 mutations in tumorigenesis are still lacking. Nonetheless, at the cellular level, the decreased binding of ING1 to H3K4me3 has been shown to result in inefficient DNA damage repair and apoptosis 75 . InG2, an InG1-related member that is also downregulated in many types of solid tumours [71] [72] [73] , initiates an acute response to silence proliferative genes, including cyclin D1 and MYC, and decelerates the cell cycle after DNA damage 14 (FIG. 2d) . This response relies on the ability of ING2 to bind to H3K4me3 marks that are associated with proliferative genes, followed by the recruitment and/or stabilization of the ING2-associated repressors HDAC1 and HDAC2 (REFs 14, 78) (FIG. 2d) . Eventually, histone deacetylation occurs at proliferative genes, their expression is downregulated, and cell cycle progression is halted 14 . As the H3K4me3 level at these genes remains the same before and after DNA damage 14 , it is still poorly understood what causes the recruitment of ING2 to proliferative genes after DNA damage. Recently, the association of ING2 with chromatin has been linked to phosphatidylinositol-5-phosphate (PtdIns(5)P), a lipid ligand of ING2 that was found to accumulate in the nucleus after cellular stress 14, 83 . The binding surface for PtdIns(5)P in ING2 is located at the C terminus, which includes a small portion of the PHD finger and a lysine-and arginine-rich polybasic region 84 . This polybasic region is found only in ING1 and ING2 (REFs 71, 73) . Further investigation is required to dissect how multivalent interactions between INGs, signalling transducers and histone modifications are coordinated to execute an efficient response to DNA damage and cellular stress. Downregulation, allelic loss and somatic mutation of ING3 and ING4 has also been found in cancer 71, 72 . Recognition of H3K4me3 is crucial for ING4 and ING5-HBo complexes to promote genotoxic stressinduced apoptosis and to inhibit anchorage-independent cell growth [76] [77] [78] . Association between the ING4 and ING5 PHD finger and H3K4me3 modulates the substrate 19, 20 and histone acetylation by the double bromodomain of TAF1 (REF. 17 ) and binding to specific DNA elements (TATA-binding protein (TBP) to the TATA box) anchor and/or stabilize the TFIID complex to core promoters 19, 20 . b | Both the recognition of H3K4me3 by the RAG2 PHD finger and binding of RAG1-RAG2 complexes to recombination signal sequences are crucial for recruiting and/or stabilizing the RAG1-RAG2 complex to V(D)J gene segments during B and T cell development 18, 21 . c | In acute myeloid leukaemia, chromosomal translocation nucleoporin 98 (NUP98)-jumonji AT-rich interactive domain 1A (JARID1A) or NUP98-PHF23 fuses the amino terminal part of a nucleoporin protein, NUP98, to an H3K4me3-binding PHD finger of JARID1A or PHF23 (REF. 22 ). This prevents the removal of H3K4me3 and addition of H3K27me3 thus enforcing the expression of leukaemia-associated oncogenes such as Hoxa9 and Meis1 (REF. 22 ). d | On DNA damage, H3K4me3 is a mark to recruit and/or stabilize the inhibitor of growth 1 (ING1) and ING2 repressive complexes to genes responsible for cell proliferation such as Myc and cyclins, leading to gene repression and the halt of cell cycle progression. A subset of cancer-associated somatic mutations of ING1 specifically interferes with the binding to H3K4me3/2 and proper response to DNA damage 14, 18, 75 . e | Recognition of H3K4me3 by the PHD finger of Pygopus (Pygo) has been suggested to be crucial for efficient activation of the Wnt signalling pathway 89 . APC, adenomatous polyposis coli; EZH2, enhancer of zeste homolog 2; GSK3β, glycogen synthase kinase 3β; HDAC, histone deacetylase. LEF1, lymphoid enhancer-binding factor 1 (also known as TCF). 
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A skeletal disease characterized by the development of benign cartilage-capped bone tumours growing outwards from the bone surface, resulting in various orthopaedic deformities.
specificity of the HBo complexes, making H3K4me3-containing nucleosomes a preferred substrate 76, 77 . using genome-wide chromatin immunoprecipitation (ChIP)-chip analyses, Hung et al. 77 observed that, after DNA damage, the recruitment of ING4-HBo complexes to the downstream targets is enhanced, followed by increased levels of H3 acetylation and transcriptional activation. Confirmed target loci include many tumour suppressor genes such as PHD2 (also known as EGLn1 and HPH2) and exostosin 1 (EXT1) 76, 77 . PHD2 is an inhibitor of hypoxia-inducible factor (HIF) and its downregulation results in increased angiogenesis in tumour tissues and the promotion of tumorigenesis 85 . Mutations in EXT1 and EXT2 are responsible for multiple osteochondroma, a skeletal disease that is characterized by benign bone tumours 86 . The misregulation of these potential tumour suppressors needs to be further examined in primary tumour samples and animal models harbouring loss of InG4.
Notably, both types of ING complexes (ING1-ING2 and ING4-ING5) seem to engage tumour suppressive activities 74 . Despite having opposite effects on transcriptional regulation 73, 78 , different INGs can apparently target different sets of genes -both oncogenic and tumour suppressor loci 14, 77 . However, this targeting specificity of distinct INGs cannot be determined by their PHD fingers, as they all bind to H3K4me3. Nevertheless, reading of H3K4me3 by the PHD finger is a crucial step for efficient chromatin binding and DNA damage-or stress-induced responses 14, [75] [76] [77] . Many other questions remain unsolved. For example, do different ING-containing complexes cooperate? And how is the interaction of p53 and other DNA-binding factors involved in these cellular responses 81 ? It is also important to appreciate how events such as sensing and signalling of DNA damage, assembly and recruitment of ING complexes, chromatin recognition and modulation, the subsequent transcriptional regulation, DNA repair and chromatin restoration post-repair, are integrated.
Pygopus, a factor that links Wnt-β-catenin signalling to H3K4 methylation. Mutations in components of the Wnt-β-catenin pathway lead to oncogenesis in several tissue types 87 . Pygopus (Pygo) has recently been identified as a crucial factor for efficient Wnt-β-catenin signalling 87, 88 . Pygo interacts with BCL9, an adaptor protein that directly associates with β-catenin 89 (FIG. 2e) .
The C terminus of all Pygo homologues (pygopus in Drosophila melanogaster, and PyGo1 and PyGo2 in mammals) contains a PHD finger, which uses two surfaces to interact with BCL9 and H3K4me2/3 simultaneously (FIG. 2e) ; the binding of H3K4me2/3 by Pygo is enhanced by its association with BCL9 (REF. 89 ). Pygo2 was found highly expressed in mammary progenitor cells and upregulated in breast cancer cells, and the H3K4me2/3-binding property of PyGo2 seems to be crucial for the cell growth of breast cancer cells 90, 91 . However, a separate study indicates that the abolition of interaction between H3K4me2/3 and pygopus does not interfere with the activation of Wnt signalling in D. melanogaster 89, 92 . Further investigation of cross-talk among pygopus, Wnt-β-catenin signalling and histone modifications needs to be carried out to address these differences.
Histone methylation is mis-erased in cancer Histone lysine demethylases (HDMs), especially those that remove methylation on H3K4 and H3K27, are found mutated or deregulated in human cancer (TABLE 1) . . b | Cooperation between histone methyltransferases and demethylases, exemplified by mixed lineage leukaemia (MLL)-ubiquitously transcribed tetratricopeptide repeat X chromosome (UTX), MLL-JMJD3 interactions and enhancer of zeste homolog 2 (EZH2)-jumonji AT-rich interactive domain 1 (JARID1) interactions, underlies changes in H3K4me3 and H3K27me3 at oncogenes such as Hoxa9, a process that is perturbed by leukaemia oncoproteins, such as NUP98-JARID1A (FIG. 2c) or MLL fusions. c | On RAS signalling-induced stress, a complex switch in histone methyltransferases and demethylases underlies activation of the tumour suppressor locus INK4B-ARF-INK4A and the subsequent induction of senescence [101] [102] [103] 105, 106, 123 . In cancer cells, overexpression of EZH2 and JHDM1, or downregulation of JMJD3 interferes with such a switch in the chromatin state and therefore the appropriate senescence response 105, 106, 124 . HDAC, histone deacetylase; MTAs, metastasis-associated proteins; Pol II, RNA polymerase II.
Syngeneic tumour transplantation model
A model of tumorigenesis produced by inoculating mouse or rat tumour cells into a corresponding immunocompetent mouse or rat. syngeneic tumour models have a normal host immune response and tumour microenvironment, and therefore more closely resemble a biologically relevant situation than xenograft models that use immunodeficient mice.
Next-generation sequencing
A still-developing technology to sequence DNA in a massively parallel fashion, therefore sequencing is achieved at a much faster speed and lower cost than traditional gel-based methods. This technology makes direct sequencing of large numbers of human patient samples possible, including those from cancers.
Misregulation of H3K4-specific demethylases in cancers.
LSD1 is the first histone demethylase (HDM) that was isolated by Shi and colleagues, and this nuclear amine oxidase can convert dimethyl or monomethyl H3K4 to the unmodified state 93 . LSD1 was purified as a stable component of several HDAC-containing transcriptional repressor complexes 93 . Recently, one such repressive complex, LSD1-Mi-2-NuRD-HDACs (FIG. 3a) , has been shown to inhibit metastasis in breast cancer 94 . LSD1 removes H3K4me2/1 from several downstream targets that include the pathways involving transforming growth factor-β (TGFβ) signalling, cell growth, and migration and invasion 94 . As a result, the expression of these targets is repressed in breast cancer cells 94 . TGFβ1, a key regulator of epithelial-to-mesenchymal transitions and tumour metastasis, is a crucial downstream effector that is inhibited by LSD1-Mi-2-NuRD complexes 94 . Knocking down LSD1 increases the invasive and metastatic potential of breast cancer cells, whereas overexpression of LSD1 suppresses the invasiveness of breast cancer cells 94 . LSD1 was found downregulated in breast carcinoma tissues 94 . In contrast to its canonical functions, LSD1 also interacts with androgen receptor (AR). This LSD1-AR complex erases methylation of H3K9, a repressive marker, thus leading to the activation of AR signalling in prostate cancer cells 95 . In addition, LSD1 also targets non-histone substrates such as p53. Lysine-specific demethylation of p53 by LSD1 represses p53-induced transcriptional activation and apoptosis 23 . These observations show that LSD1 has both tumour suppressive and oncogenic functions, and these activities are dependent on cellular contexts and substrate differences.
The understanding of histone demethylation quickly proceeded with the identification of a larger and more versatile family of HDMs -the jumonji family of lysine demethylases 6 . The jumonji family of HDMs differ from LSD1 in that these hydroxylases can remove lysine trimethylation 6 . JArID1A, a member of H3K4me3/2-specific jumonji demethylases, was found translocated in myeloid leukaemia (FIG. 2c) . JArID1b (also known as PLU-1 and KDM5b), a related H3K4me3/2 HDM gene, was found overexpressed in advanced stages of breast and prostate cancer 96, 97 . JARID1B facilitates the G1/S transition in the cell cycle and attenuates the mitotic spindle checkpoint of cancer cells 96, 98 . using a syngeneic tumour transplantation model, yamane et al. 96 showed that JArID1b overexpression promotes the growth of mammary carcinoma. JARID1B represses metallothionein genes and several known tumour suppressor genes (brCA1 and caveolin 1) by inducing the erasure of H3K4me3/2 (REFs 96, 98) . In a recent large-scale next-generation sequencing of primary renal cell carcinoma (RCC) genomes, Dalgliesh et al. 99 discovered several recurrent mutations that inactivate histone-modifying enzymes, including truncating mutations of JArID1C (~3% of all RCC samples) and SETD2 (~3%), which is a histone H3 lysine 36-specific methyltransferase gene 99 . Inactivation of JArID1C, the third member of the H3K4me3/2-specific HDM genes, is correlated with the transcriptional alteration of a specific gene signature in RCC tumour samples 99 . Most RCCs harbouring JArID1C mutation also contain a mutation at von Hippel-Lindau (VHL), a negative regulator of HIF, suggesting that the JArID1C and VHL mutations may cooperate in driving the tumorigenesis of RCC 99 . It is curious that both overexpression and loss-of-function mutations of the JARID1 gene family have been suggested to contribute to oncogenesis, although in different cancer types (TABLE 1) .
JHDM1b (also known as fbXL10, nDY1 and KDM2b) and JHDM1A (also known as fbXL11, nDY2 and KDM2A) encode another family of histone demethylases that may harbour dual methylation-erasing activities for H3K36me2/1 and H3K4me3 (REFs 100-102 ). In a screen that was based on retroviral integration-induced T cell lymphomas, Pfau et al. 103 found that upregulation of JHDM1b is a common event in T cell lymphomas. JHDM1B directly represses the tumour suppressor locus Ink4b-Arf-Ink4a by erasing H3K36me2 and/or H3K4me3 (REFs 101-103) . Both JHDM1B and the related JHDM1A inhibit replicative senescence and oncogeneinduced senescence, which are a crucial barrier of oncogenesis [101] [102] [103] . JHDM1b is downregulated after senescence induction in normal tissues, and acquired expression of JHDM1b in tumours prevents cell senescence, thus facilitating cancerous transformation 101, 102 (FIG. 3c) .
Misregulation of H3K27-specific demethylases in cancers. Sporadic inactivating mutations of ubiquitously transcribed tetratricopeptide repeat X chromosome (UTX), an H3K27me3/2-specific HDM gene, have recently been reported in a subset of multiple myeloma, oesophageal squamous cell carcinoma and renal cell carcinoma 104 . Restoration of UTX in UTX-mutated cancer cells reduced H3K27me3 at tested targets and slowed cell proliferation 104 . JMJD3, a related H3K27me3/2-specific HDM gene, was found upregulated during RAS-induced senescence, and opposite to the action of JHDM1 and EZH2, JMJD3 activates the Ink4a-Arf locus 105, 106 (FIG. 3c) .
The expression of JMJD3 has been found downregulated in various cancers, including lung and liver cancer 105, 106 . These observations indicate putative tumour suppressive roles for uTX and JMJD3. Despite emerging evidence that links HDMs to cancer, it remains to be investigated using more rigorous assays whether the observed mutation is causal or merely the consequence of tumorigenesis.
cooperation of histone modifiers one complication of classifying writing, reading and erasing histone modifications is that these processes often function in a concerted way. For example, some histone modification writers or erasers, such as MLL or JARID1A, harbour an intrinsic PHD finger module to read H3K4me3 (TABLE 2) . Currently, it is unclear how this reading property is involved in the writing and erasing steps of histone methylation. In the context of leukaemia induction, NuP98-JARID1A (FIG. 2c) , a translocation form of JARID1A, loses its histone methylation erasing activity and relies on the H3K4me3-reading PHD finger to initiate leukaemogenesis 22 . In addition, histone modifiers often work together on different histone modification sites simultaneously to coordinate a robust response. For instance, uTX is a stable component of the MLL2-and MLL3-containing complexes, which erase H3K27me3 and also write H3K4me3 at target chromatin 107 . Consistent with the action of uTX, MLL is recruited to the Ink4a locus in oncogene-induced checkpoint responses, and uTX and MLL may cooperate to promote InK4a expression and suppress cancerous transformation 108 (FIG. 3c) . Similarly, JHDM1B and JARID1A were reported to interact with EZH2 (REFs 102,109) , and JMJD3 interacts with MLL 110 . In these scenarios, there is a common theme centred on the epigenetic repression process of the tumour suppressor InK4b-Arf-InK4A locus in cancer cells. This features the elimination of active modifications (H3K4me3) and the addition of repressive chromatin modifications (H3K27me3 or DNA methylation), which is accomplished by cooperation between histone demethylase deregulation (JARID1B, JHDM1B, uTX and JMJD3), histone methyltransferases (EZH2 overexpression) and/or DNA hypermethylation to establish a stable silenced state of the INK4B-ARF-INK4A locus (FIG. 3c) .
conclusions and future directions Histone modification, as exemplified by H3K4me3 and H3K27me3 in this Review, provides a crucial regulatory measure for defining cellular context and governing gene transcription, v(D)J DNA recombination, DNA damage repair and many other DNA-templated processes. Rapidly increasing evidence has indicated that miswriting, misreading, and/or mis-erasing of histone modifications contributes to the initiation and development of human cancers. However, the underlying mechanisms of chromatin regulation in oncogenesis are complex and remain to be delineated in a cellular context-dependent manner.
First, it remains unclear whether many mutations and deregulations of epigenetic players are the 'drivers' or 'passengers' of oncogenesis. More rigorous evidence is generally lacking to establish the causality of deregulation of the writing, reading and erasing of histone modification events in oncogenesis. Generating animal models with ING mutations will be needed for defining their oncogenic roles, and as useful tools for understanding the mechanisms driving oncogenesis. Similar issues can be applied to the inactivating mutations of JArID1C found in renal carcinoma 99 or for EZH2 in germinal centre diffuse large B cell lymphoma 65 . In addition, the regulatory mechanisms through histone modification can be cell type or context specific. To dissect the misregulation of histone modifications and epigenetic imbalances in cancer cells, it is important to understand how normal cells use dynamic chromatin modifications to establish the appropriate epigenetic homeostasis and induce state transitions at crucial loci encoding oncogenes (for example, the HoX gene cluster in haematopoietic lineages (FIG. 3b) ) or tumour suppressor genes (for example, the InK4b-Arf-InK4A cluster (FIG. 3c) ) in normal developmental and cellular contexts. For example, although DoT1L-mediated H3K79me and transcription elongation have been proposed as mechanisms responsible for aberrant gene activation that are hijacked by MLL fusions in leukaemia cells (FIG. 2b,c) , they fail to explain why the MLL fusion, but not wildtype MLL, is refractory to the silencing mechanism that can turn off MLL targets in haematopoiesis. Recently, it has been shown that the artificial addition of the MLL PHD fingers, a portion not retained in MLL fusions, can inhibit MLL fusion-induced transformation 111, 112 . These studies shed light on the dynamic regulation of wildtype MLL complexes and the loss of such an inhibitory mechanism may contribute to the conversion of the MLL fusion to a constitutive activator 111, 112 . This inhibitory effect seems to be due to the recruitment of the repressive factors cyclophilin 33 (CyP33) and HDACs by the third PHD finger of MLL 112 and/or the inhibition of MLL targeting 111 . The third PHD finger of MLL has been predicted to bind to H3K4me3/2 (REF. 5 ). So far, CyP33 has only been reported as a PHD finger ligand for MLL 112 , thus this mechanism may be MLL specific. Further efforts are needed to understand how the PHD fingers distinguish normal MLL complexes and their leukaemia fusion forms in terms of transcriptional regulation.
Furthermore, it is unclear how the gene-target specificity, if any, of many histone-modifying or modificationreading factors is achieved. For example, the recruitment of different sets of INGs to distinct genomic loci cannot be explained by H3K4me3 recognition. Although menin and LEDGF were found to be required to tether MLL to its target gene loci 31 , it is far from clear how MLL fusions are targeted to their downstream genes in leukaemia. Besides the intrinsic motifs that are associated with chromatin and histone modification 17 , histone modification reading and enzymatic factors can be recruited to their targets by DNA-binding factors, co-activators, co-repressors, and Pol II-associated mediators and machineries. For example, nuclear receptors assemble different sets of cofactors and histone-modifying enzymes after the activation or depletion of hormone signalling 113 , and we refer readers to some comprehensive reviews on this topic [113] [114] [115] . Finally, as some histone-modifying enzymes also function on non-histone substrates 24, 25, 116 , it becomes difficult to ascribe observed results to histone modification alone. Experiments need to be carefully designed, ideally by applying a combination of approaches and methodologies to dissect the effects that originate from histone modification.
Is it time for the therapeutic intervention of epigenetic players that modify or interpret chromatin modifications? The first goal is to identify the crucial epigenetic factors that have well-defined roles in the initiation or development of cancers. For example, the H3K4me3-binding pocket is a potential therapeutic target for the treatment of the leukaemia-harbouring translocations NuP98-JARID1A and NuP98-PHF23 (REF. 22 ). In addition, many histone-modifying enzymes are ideal targets as their enzymatic activity is druggable 56 . However, the enthusiasm of developing such inhibitors can be curbed by a general concern of potential side effects and complications. For example, the H3K4me3-binding pockets of different PHD finger proteins (TABLE 2) have a high structural similarity 15, 16, 20, 22 , and these factors are involved in several important cellular processes, such as transcription 19 . However, we remain confident that further investigation will lead to the discovery of relatively specific druggable epigenetic factors that represent the Achilles heel of tumour cells.
In support, the clinical success of HDAC inhibitors in cutaneous T cell lymphoma and DNA demethylating agents in myelodysplastic syndrome offers a compelling argument 4, 117, 118 . Recently, a genomic study has shown that pharmacological doses of all-trans retinoic acid induces a specific effect on histone H3 deacetylation in PML-RARα fusion-positive acute promyelocytic leukaemia cells (PMLs), and the change in H3 acetylation underlies differentiation therapy and epigenetic therapy of PML 119 . This study also provides a rationale for developing HDAC inhibitors as an alternative therapy for patients with PML that are refractory to current standard treatments. With the rapidly growing attention and new discoveries of epigenetic factors that function to govern a steady-state balance or the output of histone modifications, there is considerable promise and excitement on the horizon.
